Recurrence Risk – Medxy AI

RETREAT Score Stratifies Long-Term Hepatocellular Carcinoma Recurrence Risk After Liver Transplantation in Real-World Practice

By MedXY 06/07/2026

A single-center validation study shows the RETREAT score reliably predicts long-term HCC recurrence after liver transplantation and identifies patients with markedly different recurrence-free and overall survival trajectories.

Diabetes & Endocrinology news Oncology

Calcitonin Doubling Rate Sharpens Postoperative Recurrence Risk Stratification in Medullary Thyroid Carcinoma With Biochemical Persistent Disease

By MedXY 05/04/2026

In medullary thyroid carcinoma with biochemical persistent disease after surgery, an early postoperative calcitonin doubling rate of at least 0.3/year strongly identified patients at higher recurrence risk and may help tailor surveillance intensity.

General Surgery news Oncology

Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors

By MedXY 12/22/2025

A multi-center study in JAMA Surgery introduces a validated 13-point risk score to identify recurrence risk in LN-negative PanNET patients, revealing that tumor size, grade, and lymphovascular invasion are critical prognostic drivers even when nodes are clear.